A minor CYP450 metabolite of arachidonic acid that stimulates vasodilation of rabbit kidney.

An internal standard for the quantification of 4-HNE mercapturic acid by GC- or LC-MS.

The product of nitration of linoleate by NO-derived reactive species; activates PPARγ (Ki = 133 nM), inducing CD36 expression in macrophages, adipocyte differentiation, and glucose uptake; can also be metabolized to produce nitrite derivatives which in turn form NO, leading to increased cGMP production.

11-trans LTD4 is a C-11 double bond isomer of LTD4. LTD4 undergoes slow temperature-dependent isomerization to 11-trans LTD4 during storage. 11-trans LTD4 retains about 10-25 % of the potency for contraction of guinea pig ileum, trachea and parenchyma compared to LTD4. It exhibits an ED50 ranging…

A 5-series LO derived from EPA; contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4, yet does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4.

An aspirin-triggered lipoxin that inhibits LTB4-induced chemotaxis, adherence, and transmigration of the neutrophils with twice the potency of LXA4 demonstrating activity in the nM range.

11-trans LTC4 is a C-11 double bond isomer of LTC4. LTC4 undergoes slow temperature-dependent isomerization to 11-trans LTC4 during storage. 11-trans LTC4 is produced in smaller amounts relative to LTC4 in ionophore-stimulated HMC-1 cells (a human mast cell line) and equine eosinophils, but not in…

Less potent than AEA (Item No. 90050) at the CB1 receptor (Ki = 600 versus 90 nM); inhibits FAAH.

The racemic version of a CYP450 metabolite of arachidonic acid that dose-dependently stimulates vasodilation of the rabbit kidney.

The diol resulting from the sEH opening of (±)11(12)-EET; contracts artery rings with approximately 70% of the magnitude of (±)11(12)-EET.

An internal standard for the quantification of trans-resveratrol by GC- or LC-MS.

A stable analog of TXA2; unlike other TP receptor agonists, it inhibits platelet aggregation (IC₅₀ = 4-5 µM).

(±)11-HDHA is an autoxidation product of DHA in vitro. It is also produced from incubations of DHA in rat liver, brain, and intestinal microsomes. DHA is metabolized to 11(S)-HDHA by human platelets and canine retina. In addition to 11(S)-HDHA, 14(S)-HDHA is also produced by platelets.…

A major CYP450 metabolite of arachidonic acid that is released from the kidney in response to angiotensin II; a potent vasodilator of renal preglomerular vessels; blocks 20-HETE-induced vasoconstriction of renal arterioles at 1 µM.

Key urinary metabolite of PGD2; represents approximately 1% and 4% of the infused radiolabeled dose in monkeys and humans, respectively.

A derivative of (±)8(9)-EET which is stable enough to ship and handle routinely.

13,14-dihydro-19(R)-hydroxy PGE1 is the theoretical metabolite of 13,14-dihydro PGE1 by ω-1 hydroxylase. There are no known reports on its biosynthesis or biological activity.

(±)8-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid.

A bioactive macrolide derived from sponges that binds monomeric actin, preventing actin polymerization both in vitro (Kd = 0.2 μM) and in cells (0.5 μM).

A potential metabolite of PGD2, presumably produced from the known metabolite 13,14-dihydro-15-keto PGD2.

15(R)-HEDE is isolated by the chromatographic resolution of (±)15-HEDE. There are no reports of biological activity associated with 15(R)-HEDE in the literature.

The lipoxins are trihydroxy fatty acids containing a 7,9,11,13-conjugated tetraene. LXA4 was first described as a metabolite of 15-HpETE and/or 15-HETE when added in vitro to isolated human leukocytes. The material obtained in this manner consists of at least four distinct isomers: 5(S), 6(S);…

8(S)-HETrE is a monohydroxy PUFA produced by rabbit neutrophil lipoxygenase when DGLA is used as a substrate. Although the biological activities of 8(S)-HETrE have not been well characterized, it is expected to behave similarly to 8(S)-HETE.

A metabolite of lipoxygenase-mediated oxidation of DPA; activates Nrf2-dependent antioxidant gene expression, acts as a PPARγ agonist (EC₅₀ = ~200 nM), and inhibits pro-inflammatory cytokine and nitric oxide production at biological concentration ranges (5-25 µM).

A proposed anti-inflammatory EPA metabolite that has been shown to promote inflammatory resolution in numerous disease models, including experimental colitis, asthma, atherosclerosis, type 2 diabetes, and HSV-1-induced stromal keratitis.

(±)15-HETE is one of the six monohydroxy fatty acids produced by the non-enzymatic oxidation of arachidonic acid. The biological activity of (±)15-HETE is similar to that of its constituent enantiomers (Item Nos. 34720 and 34710).

A potential cytochrome P450 metabolite of N-arachidonoyl taurine that may activate TRPV1 and TRPV4.

An internal standard for the quantification of (±)14(15)-DiHET by GC- or LC-MS.

.DELTA.17-6-keto PGF1α is the non-enzymatic hydrolysis product of PGI3. PGI3 is a COX pathway metabolite of EPA in various tissues such as seminal vesicles, lung, PMNL, and ocular tissues.

An internal standard for the quantification of DHA by GC- or LC-MS.

A 13R,14S-dihydroxy DHA formed by recombinant human macrophage 12-LO and sEH co-incubated with DHA; reduces neutrophil infiltration in a mouse model of peritonitis and enhances human macrophage phagocytosis of zymosan A.

15-OxoETE is produced by oxidation of the 15-hydroxyl of 15-HETE. Whether this is a major pathway of 15-HETE metabolism is yet to be clearly established.